Novo Nordisk submitted a New Drug Application to the FDA in December 2025, and review is expected during 2026
[DOI] [PubMed] [Google Scholar] 26.Ntzouvani A., Nomikos T., Panagiotakos D., Fragopoulou E., Pitsavos C., McCann A., Ueland P., Antonopoulou S
Statistics For PTR-MS statistical analyses, data were analyzed using the Students t-test to compare the acquisition signals obtained in presence of OM, heated OM or mucus with the control acquisition signals without OM or without mucus
Volume 226
Thus, despite several years with a clinically confirmed POTS diagnosis, which may be associated with altered insulin dynamics, HbA1c was normal